Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2886 of 3330
Next
>>
>
72126 to 72150 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
HCC70	TNBC	Basal A	Temsirolimus	MTOR	MTOR	133	uM	12400.168	0.6057	0.3708	1.3275
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	0.000341	uM	10694.144	1.0870	1.0786	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	0.00171	uM	10694.144	1.0086	1.0080	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	0.00853	uM	10694.144	0.8846	0.8898	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	0.0427	uM	10694.144	0.9779	0.9795	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	0.213	uM	10694.144	0.9095	0.9142	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	1.07	uM	10694.144	0.8226	0.8274	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	5.33	uM	10694.144	0.7302	0.7295	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	26.7	uM	10694.144	0.6692	0.6612	2.1636
Hs 578T	TNBC	Basal B	Temsirolimus	MTOR	MTOR	133	uM	10694.144	0.0082	-0.7824	2.1636
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.000341	uM	10816.144	1.0627	1.1376	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.00171	uM	10816.144	0.9988	0.9975	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.00853	uM	10816.144	0.9704	0.9355	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.0427	uM	10816.144	0.6913	0.3357	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.213	uM	10816.144	0.6829	0.3179	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	1.07	uM	10816.144	0.6630	0.2761	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	5.33	uM	10816.144	0.6001	0.1444	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	26.7	uM	10816.144	0.4693	-0.1255	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	133	uM	10816.144	0.0116	-0.9847	0.9146
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.000341	uM	12319.168	0.9433	0.8814	0.9560
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.00171	uM	12319.168	0.8290	0.6438	0.9560
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.00853	uM	12319.168	0.9131	0.8185	0.9560
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.0427	uM	12319.168	0.6596	0.2942	0.9560
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	0.213	uM	12319.168	0.6398	0.2535	0.9560
LY2	HR+	Luminal	Temsirolimus	MTOR	MTOR	1.07	uM	12319.168	0.6426	0.2592	0.9560

|<
<<
Previous
Page 2886 of 3330
Next
>>
>
72126 to 72150 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)